Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

Topics

2025 American Society of Clinical Oncology (ASCO) Annual Meeting

, CancerNetwork® put together an X Spaces discussion hosted by Stephen Liu, MD; and Joshua Sabari, MD, to highlight the most intriguing and practice-changing lung cancer abstracts. Discussed topics ranged from long-term follow-up with commonplace therapies to an analysis of what time of day is best to administer immunochemotherapy.

Liu, an associate professor of medicine at Georgetown University and the director of thoracic oncology and head of developmental therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the New York University Grossman School of Medicine and the director of high reliability organization initiatives at the Perlmutter Cancer Center, shared expert insights on the latest non–small cell lung cancer (NSCLC) and SCLC breakthroughs.

Trials of note that they discussed included:

The phase 3 DeLLphi-304 trial (NCT05740566)

: "Tarlatamab (Imdelltra) vs Chemotherapy (CTx) as Second-Line (2L) Treatment for Small Cell Lung Cancer (SCLC): Primary Analysis of Ph3 DeLLphi-304"

: "Lurbinectedin (Lurbi) + Atezolizumab (Atezo) as First-Line (1L) Maintenance Treatment (tx) in Patients (pts) With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Results of the Phase 3 IMforte Trial"

The phase 3 CheckMate 816 trial (NCT02998528)

: "Overall Survival With Neoadjuvant Nivolumab (NIVO) + Chemotherapy (Chemo) in Patients With Resectable NSCLC in CheckMate 816"

The phase 3 PACIFIC15 trial (NCT05549037): "Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-Free and Overall Survival in Patients With Non–Small Cell Lung Cancer"

The phase 3 Beamion LUNG-1 trial (NCT04886804): "Patient-Reported Outcomes (PRO) Evaluating Physical Functioning and Symptoms in Patients With Pretreated HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Beamion LUNG-1 trial"

The phase 3 ARTEMIA trial (NCT06472245): "Phase 3 Trial of the Therapeutic Cancer Vaccine OSE2101 Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer and Secondary Resistance to Immunotherapy"

Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of ph3 DeLLphi-304. 

. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008

Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. 

2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006

Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC in CheckMate 816. 

. 2025;43(suppl 17):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000

Zhang Y, Huang Z, Zeng L, et al. Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. 

. 2025;43(suppl 16):8516. doi:10.1200/JCO.2025.43.16_suppl.8516

Sabari JK, Nadal E, Hendriks L, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial. 

2025;43(suppl 16):8620. doi:10.1200/JCO.2025.43.16_suppl.8620

Liu SV, Guibert C, Tostivint EP, et al. Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. 

. 2025;43(suppl 16):TPS8651. doi:10.1200/JCO.2025.43.16_suppl.TPS8651

ASCO Annual Meeting: Lung Cancer

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting. 

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

In the second edition of a special podcast series, CancerNetwork

 spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about the best practices for incorporating recently approved bispecific antibodies into cancer care. This discussion focused on clinical trial results, administration protocols, and adverse effect (AE) management strategies related to the use of tarlatamab-dlle (Imdelltra) for patients with small cell lung cancer (SCLC).

Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital.

The conversation opened with Morgensztern highlighting tarlatamab’s mechanism of action as an agent that targets DLL3. He then reviewed prior efficacy data that the therapy demonstrated in the phase 1 DeLLphi-300 trial (NCT03319940) and the phase 2 DeLLphi-301 trial (NCT05060016). Of note, the 

 as the first available T-cell engager immunotherapy for patients with extensive-stage SCLC who have progressed on prior platinum-containing chemotherapy in May 2024 based on data from the DeLLphi-301 trial.

Additionally, Flanagan detailed strategies for monitoring and mitigating the most common AEs associated with tarlatamab in this patient population, which include cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. Mann then outlined considerations for properly dosing and administering the agent, highlighting factors that clinicians should keep in mind when continuing treatment in an inpatient or outpatient setting.

The group also spoke about clinical decision-making related to patients who have brain metastases, which included processes for adjusting the dose of tarlatamab and sequencing the bispecific agent with radiotherapy.

FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. FDA. May 16, 2024. Accessed March 14, 2025. https://tinyurl.com/48k34rw5

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

In a conversation with CancerNetwork®, Gregory Peter Kalemkerian, MD, spoke about the publication of updated guidelines for managing small cell lung cancer (SCLC) with systemic therapy, which was developed by the American Society of Clinical Oncology (ASCO) in collaboration with Ontario Health (Cancer Care Ontario).

Kalemkerian, a clinical professor at The University of Michigan and senior author of the guidelines, discussed developments in the SCLC field that inspired the creation of the revised guidelines since the last publication from ASCO in 2015.

 Although the latest guidelines contained recommendations concerning treatment modalities such as surgery and radiotherapy, Kalemkerian said that the biggest advances related to the integration of immunotherapy into frontline treatment for patients with extensive-stage SCLC (ES-SCLC).

Specifically, Kalemkerian highlighted the use of immunotherapeutic agents such as durvalumab (Imfinzi) and atezolizumab (Tecentriq), which have demonstrated long-term improvements in survival of those with ES-SCLC. The guideline authors issued a strong recommendation backed by high-quality evidence for the frontline use of carboplatin plus etoposide or cisplatin plus atezolizumab or durvalumab followed by maintenance immunotherapy in patients with ES-SCLC who have no contraindications to immunotherapy.

 Additionally, there was no evidence supporting the continuation of immunotherapy for those with relapsed SCLC and progressive disease following maintenance immunotherapy based on an informal consensus.

With respect to other updates in the guidelines, Kalemkerian spoke about optimal treatment strategies for patients with poorer performance statuses as well as the potential role of biomarkers in SCLC. Although there are currently no validated biomarkers that have demonstrated utility in the management of SCLC, he stated that it was necessary to overhaul how practices understand how diseases like SCLC develop and grow to help improve patient outcomes.

“I would like people to pay attention to SCLC a little bit,” Kalemkerian said. “Non–small cell lung cancer has gotten a lot of the press and hype over the last 20 years or so since targeted therapy came out for that disease. Before that, we all thought SCLC was where we were going to be making advances, and we were wrong. We’re on the cusp of understanding the disease better and utilizing that understanding to advance newer strategies for trying to treat these patients.”

Khurshid H, Ismaila N, Bian J, et al. Systemic therapy for small-cell lung cancer: ASCO-Ontario Health (Cancer Care Ontario) guideline. 

. 2023;41(35):5448-5472. doi:10.1200/JCO.23.01435

Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. 

. 2015;33(34):4106-4111. doi:10.1200/JCO.2015.63.7918.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Check out the previous podcast episodes in this series:

Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer

Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

Episode 3: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment

In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center about the occurrence of toxicities associated with treatment, quality of life for patients, and managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin (Zepzelca) and trilaciclib (Cosela), as well as chemotherapy and immunotherapy.

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Oncology Peer Review On-The-Go: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

In the second part of our 4-part series on small cell lung cancer (SCLC), CancerNetwork® continued its conversation with Wade Iams, MD, a thoracic medical oncologist at Vanderbilt University Medical Center. Iams turned attention towards different treatment options that are currently available for patients with relapsed/refractory SCLC. Among others, Iams touched on lurbinectedin (Zepzelca), topotecan, and some of the crucial clinical trials associated with treatment options for SCLC. These studies included a phase 2 basket trial (NCT02454972) that assessed the use lurbinectedin as a second-line therapy in relapsed SCLC and phase 3 ATLANTIS trial (NCT02566993), which examined second-line lurbinectedin in combination with doxorubicin in patients with SCLC.

Check out the first episode of this series on 

first-line therapeutic options in small cell lung cancer

Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.

Oncology Peer Review On-The-Go: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork® spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer (SCLC). Iams spotlighted the current first-line therapies that are available for patients with SCLC and the factors considered for treating patients in the first-line setting. He also discussed the phase 3 IMpower133 trial (NCT02763579) evaluating the safety and efficacy of atezolizumab (Tecentriq) in combination with carboplatin and etoposide for patients with extensive stage SCLC and the phase 3 CASPIAN trial (NCT03043872) examining the efficacy and safety of durvalumab (Imfinzi) with or without tremelimumab combined with platinum-based chemotherapy for patients with extensive stage SCLC.

In the first episode of a 4-part series, CancerNetwork® spoke with Wade Iams, MD, about the various first-line treat options that are available for patients with small cell lung cancer.

Oncology Peer Review On-The-Go: First-Line Therapeutic Options in Small Cell Lung Cancer

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field.

In the video series, Levy discussed the following:

Small Cell Lung Cancer: Risk and Prognosis

Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment

Immunotherapy for First-Line Extensive-Stage SCLC

First-Line I-O Plus Chemotherapy for Extensive-Stage SCLC

Significance of the IMpower133 Trial in Extensive-Stage SCLC

To watch more videos in CancerNetwork®’s OncView™ series, visit 

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

This special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.

OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung Cancer

As part of the OncView™ video series, CancerNetwork® spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, about updates in the management of extensive-stage small cell lung cancer (ES-SCLC).

In the video series, Socinski discussed the following:

Treatment Challenges in Extensive-Stage SCLC

Immunotherapy as First-Line Treatment for Extensive-Stage SCLC

The IMpower133 Trial in Extensive-Stage SCLC

Extensive-Stage SCLC: Implications of IMpower133

This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.

OncView™ Podcast: Front-Line Management of Extensive-Stage SCLC

 examines an article from the March issue of the Journal

 titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of recommended treatment need to be studied further. We spoke with one of the study authors, K.M. Monirul Islam, MD, PhD, of the Georgia Medical Center, to learn more about this research.

For the response perspective, we spoke with Jennifer W. Carlisle, MD, an assistant professor of hematology and medical oncology at Winship Cancer Institute of Emory University. Carlisle spoke about small cell lung cancer, how treatment refusal impacts treatment of a patient, and more.

Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

The latest episode of the podcast dissects a piece of original research from the Journal ONCOLOGY focusing on the impact of treatment refusal on patients with small cell lung cancer.

Oncology Peer Review On-The-Go: Impact of Treatment Refusal on Survival for Small Cell Lung Cancer

No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC

The median PFS and OS were 5.5 months and 11.2 months with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer. 

Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC

Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population. 

Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.

Small Cell Lung Cancer (SCLC)

Latest News